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In patients with Huntington’s disease (HD), the proteolytic activity of the ubiquitin proteasome system (UPS) is reduced in the
brain and other tissues. The pathological hallmark of HD is the intraneuronal nuclear protein aggregates of mutant huntingtin.
We determined how to enhance UPS function and influence catalytic protein degradation and cell survival in HD. Proteasome
activators involved in either the ubiquitinated or the non-ubiquitinated proteolysis were overexpressed in HD patients’ skin
fibroblasts or mutant huntingtin-expressing striatal neurons. Following compromise of the UPS, overexpression of the
proteasome activator subunit PA28c, but not subunit S5a, recovered proteasome function in the HD cells. PA28c also improved
cell viability in mutant huntingtin-expressing striatal neurons exposed to pathological stressors, such as the excitotoxin
quinolinic acid and the reversible proteasome inhibitor MG132. These results demonstrate the specific functional
enhancements of the UPS that can provide neuroprotection in HD cells.
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INTRODUCTION
Huntington’s disease (HD) is an adult onset autosomal domi-
nant inherited disease, characterized clinically by a progressive
movement and psychiatric disorder. Neuropathologically, HD is
associated with neuronal dysfunction and cell death, especially in
the caudate-putamen (striatum) region of the brain [1]. HD is
caused by mutations increasing the number of CAG repeats in
exon 1 of the huntingtin gene (IT15), which is expressed in most
cells of the human body [2]. A hallmark of the disease
neuropathology is intracellular ubiquitin positive nuclear inclusion
bodies of mutated huntingtin [3–6]. One potential cause for such
abnormal protein aggregation is dysfunction or overloading of the
ubiquitin-proteasome system (UPS), which is essential for the
clearance of short-lived, mislocated, misfolded, mutated, and
damaged proteins in eukaryotic cells [7,8].
Previously, we discovered that proteasome activities are
inhibited in striatum, frontal cortex, cerebellum and substantia
nigra of HD patients’ brain, and also in non-brain cells such as
their skin fibroblasts [9]. In HD patients, we also found increased
ubiquitin expression levels, and confirmed decreased mitochon-
drial complex II–III (MCII–III) enzyme activities in the caudate
putamen region of the brain, and decreased brain derived
neurotrophic factor (BDNF) protein levels in several brain regions
of HD patients [9]. These data indicated that UPS dysfunction
may precipitate the critical pathology of the vulnerable medium
sized spiny neurons in the striatum [9]. It is therefore of interest
therapeutically to study whether improved UPS function can
reduce the abnormal protein degradation and increase cell survival
in HD.
How does the UPS degrade abnormal proteins? The UPS is
a large multisubunit protease assembly, where protein substrates
are enzymatically processed at the catalytic sites of the central
core chamber of the 20S proteasome [10,11]. Corresponding to
the function of the different subunits of the catalytic core,
the activities of the 20S proteasome include (1) chymotrypsin-
like (after hydrophobic residues), (2) trypsin-like (after basic
residues), or (3) peptidyl-glutamyl preferring hydrolytic
(PGPH, after basic residues) activities [12,13]. When the amounts
of intracellular abnormal proteins are increased, this catalytic
core can assemble with proteasome activators (PA). There are
two types of PA: PA28 subunits for non-ubiquitinated and
PA700 subunits for ubiquitinated proteolysis, which can facili-
tate protein substrate entry and activation of proteasome func-
tion [14,15]. In this report, we first describe the effect of the
mutant huntingtin protein on UPS function in different HD
relevant cellular systems, and then demonstrate that gene transfer
of the PA subunits of the UPS can enhance abnormal protein
degradation leading to improved function and survival of cells in
HD.
RESULTS
Experimental strategy for the modification of the
UPS in HD model cells
Since HD patients predominantly show selective cell death for
medium-sized spiny neurons in caudate-putamen (striatum) in late
disease stages, but not in other tissues such as skin fibroblasts, it is
interesting to compare the effects of proteasome activators in
HD fibroblasts with HD model striatal neurons. For the HD in
vitro model systems, we chose HD patients’ skin fibroblasts
Academic Editor: Mark Cookson, Laboratory of Neurogenetics, National Institutes
of Health, United States of America
Received November 29, 2006; Accepted January 24, 2007; Published February
28, 2007
Copyright:  2007 Seo et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Funding: This work was primarily supported by NIH NS-30064 (to OI), the
Vaughan Foundation (to OI), and in part by a KRF Grant funded by the Korean
Government (MOEHRD) (KRF-2005-202-C00230) (to HS), Hanyang University (HY-
2005) (to HS) and BK21 fellowship (to WK).
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: hseo@hanyang.ac.kr
(HS); isacson@hms.harvard.edu (OI)
PLoS ONE | www.plosone.org 1 February 2007 | Issue 2 | e238
[9], which show UPS dysfunction but are not vulnerable to the
disease process. For modeling the most vulnerable cell type in
HD, we used rat embryo derived striatal neurons with inducible
mutant huntingtin expression [16]. These huntingtin-inducible
striatal neurons expressed mutant huntingtin based on the
Tet-ON-system [16] representing an early stage of targeted
vulnerable cells in HD. By comparing wild type with mutant
huntingtin overexpressing striatal neurons, we addressed the
question of the consequences of altered proteasome function.
Finally, we overexpressed proteasome activators in the HD model
cells using lentiviral gene transfer (Figure 1A), and determined
UPS function and cell viabilities after exposure to HD relevant
toxins.
Overexpression of PA28c but not S5a can up-
regulate proteasome activities in normal control
and HD patient skin fibroblasts
In a previous study, the overexpression of PA28a and b increased
chymotrypsin-like and PGPH activities in control, but not in HD
patient fibroblasts [9]. In contrast, overexpression of another
subunit, PA28c, was able to significantly increase chymotrypsin-
like and PGPH activities in both normal human control and HD
patients’ fibroblasts (Figure 1A and 1C). Nonetheless, the increase
of proteasome activities in HD patients’ fibroblasts was signifi-
cantly smaller than those seen in normal control fibroblasts after
PA28c gene-transfer (Figure 1B–1D). We next investigated the
overexpression of the S5a subunit of PA700, which is important
for the recruitment of ubiquitinated abnormal proteins into the
UPS [17,18] (see introduction). While lentiviral overexpression of
S5a increased chymotrypsin-like and PGPH activities in control
human skin fibroblasts, this did not occur in HD patient fibroblasts
(Figure 1E–1F). In fact, S5a expression increased trypsin-like
activity and marginally but significantly (p,0.05) reduced
chymotrypsin-like activity in HD fibroblasts. Notably, the effects
of the overexpression of PA28c and S5a had a larger impact on
chymotrypsin and PGPH-like activities than on trypsin activity in
both normal control and HD patients’ fibroblast cells (Figure 1B–
1G). In parallel experiments, gene-transfer of p58 (another subunit
for PA700) did not significantly alter proteasome activity in either
normal (109618% of control, p = 0.29) or HD patient fibroblasts
(112616% of control, p = 0.23).
Mutant huntingtin expressing striatal neurons show
reduced proteasome activities
To study UPS modification in the more vulnerable cells, such as
striatal neurons, we used inducible cell lines expressing the wild
type (26CAG, CTRL, control striatal neuron) or mutant N-terminal
548 amino acid fragment of huntingtin (105CAG, Htt, HD model
striatal neuron) [16]. As we showed in HD patients’ fibroblasts, we
also found that chymotrypsin-like, PGPH, and trypsin-like
proteasome activities were relatively decreasded in HD model
striatal neurons, compared to the control striatal neurons, at both
pre-differentiation (Seo and Isacson, unpublished data) and the
neuronal post-differentiation stage. Notably, control and HD
model striatal neurons showed significantly increased proteasome
activities [in control striatal neurons; chymotrypsin: 16166%
(p,0.05), PGPH-like: 14367% (p,0.05), trypsin: 13469%
(p,0.05); in HD striatal neurons; chymotrypsin: 12968%
(p,0.05), PGPH-like: 12367% (p,0.05), trypsin: 111610%
(p= 0.12)] compared to parental striatal cells (ST14A; without
exogenous huntingtin transfection). These results demonstrate that
overexpression of mutant huntingtin with expanded CAG repeats
produces a major UPS dysfunction in HD model striatal neurons
compared to control striatal neurons.
Overexpression of PA28c but not S5a increases
proteasome activities in wild type and mutant
huntingtin overexpressing striatal neurons
To provide functional and potentially therapeutic cellular
models, we next performed gene transfer of several proteasome
activator subunits including the PA28a, b and c subunits, for
the 20S proteasome, and the S5a and p58 subunits of PA700
for the 26S proteasome into the HD model striatal neurons.
After neuronal differentiation, we determined proteasome activ-
ities and also administered toxins that have been shown to elicit
HD-like pathology in control and HD model striatal neurons
(Figure 2).
Similar to the previous results in a systematic analysis in human
fibroblasts [9], the viral gene transduction of PA28a and b subunits
did not significantly alter the proteasome activities HD model
striatal neurons in this study (for example, chymotrypsin activity,
PA28a: 105612%, p= 0.11, PA28b: 115615%, p= 0.21),
compared to lenti-GFP transduction. The gene transduction of
PA p58 subunit also did not significantly alter the proteasome
activities in either control (112610% of control, p = 0.18) or HD
model striatal neurons (109612% of control, p = 0.15) compared
to lenti-GFP transduction. In contrast, PA28c subunit over-
expression produced a marked effect on proteasome activities
including trypsin-like, chymotrypsin-like and PGPH activities in
HD model striatal neurons (Figure 3A–3C). In addition, PA28c
overexpression slightly decreased huntingtin protein levels in HD
model striatal neurons after administration of doxycycline
(Figure 2B). In both control and HD model striatal neurons, S5a
overexpression caused only minor changes in the proteasome
activities tested, (Figure 3D–3F). In fact, S5a expression slightly
decreased chymotrypsin-like activity in HD model striatal neurons,
and PGPH activity in control striatal neurons. Nonetheless, S5a
slightly increased the trypsin-like activity in HD model striatal
neurons.
PA28c but not S5a improves cell survival of mutant
huntingtin expressing striatal neurons, which
showed increased vulnerability to
neuropathological toxins
We next evaluated if overexpression of PA28c and S5a lead to
improved cell function and increased cell survival in HD model
striatal neurons. We used three different HD relevant toxic stimuli:
MG132 (a reversible proteasome inhibitor), 3-NP (a mitochondrial
toxin) or QA (quinolinic acid, an excitotoxin). Cell viability of
differentiated control or HD model striatal neurons was examined
using the MTS assay, which reflects the number of viable cells
[19]. There was a dose-dependent toxicity for each toxin in control
and HD model striatal neurons. HD model striatal neurons (Htt,
105CAG) showed less cell viability after toxic exposure to MG132
(Figure 4A), 3-NP (data not shown) and QA (data not shown) than
control striatal neurons (CTRL, 26 CAG) in the same conditions.
Notably, PA28c expression significantly improved cell survival of
HD model striatal neurons (Htt, 105 CAG) compared to lenti-GFP
transduction after MG132 proteasome inhibitor treatment and
QA excitotoxicity (Figure 4A, 4B and 4D). However, PA28c
expression did not improve cell survival after mitochondrial toxin
HD Cell Survival by PA28c
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exposure (3-NP) (Figure 4C). Overexpression of the S5a subunit
did not enhance neuronal health in either control or HD model
striatal neurons (Figure 4E–4G). S5a exacerbated MG132 and QA
toxin effects, but did not alter the effects of 3-NP treatment
(Figure 4F). These data demonstrate that overexpression of the
proteasome activator subunit PA28c (but not S5a) can reduce HD
model neuronal cell damage (and death) associated with protea-
some dysfunction and excitotoxicity, but did not protect the
cellular dysfunction produced by direct mitochondrial complex II
toxicity.
Figure 1. Proteasome activities following lentiviral gene transfer of PA28c and S5a, in control and HD fibroblasts. (A) Expression levels of gene and
protein of S5a and PA28c were determined using RT-PCR and Western blot after viral gene transfer to HD fibroblasts (lane 1 and 3; lenti-GFP
transduced cells, lane 2; S5a transduced cells, and lane 4; PA28c transduced cells). (B–G) Proteasome activities were increased by lentiviral gene
transduction of PA28c. Chymotrypsin-like (B, E), PGPH (C, F) and trypsin-like (D, G) activities were detected in normal control (,36 CAG) and HD
patients’ skin fibroblasts, which overexpress PA28c (B–D) or S5a (E–G). The overexpression of PA28c increased chymotrypsin and PGPH-like, but not
trypsin proteasome activities in both normal control and HD fibroblasts compared to lenti-GFP transduction. Chymotrypsin activities and PGPH
activities were increased in control fibroblasts by overexpression of S5a. However, in HD patients’ fibroblasts, S5a did not increase PGPH activities and
slightly decreased chymotrypsin-like activities (1, p,0.05 between control and HD fibroblasts. *, p,0.05 between the gene transferred groups of
control protein GFP and PA28c or S5a). The experiments were repeated three times in triplicate.
doi:10.1371/journal.pone.0000238.g001
HD Cell Survival by PA28c
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DISCUSSION
In this study, we performed viral gene transduction of proteasome
activator (PA) subunits (a, b, c for PA28 and S5a and p58 for
PA700) to HD patients’ and control fibroblasts and to control and
HD model striatal neurons, to determine the functionality of the
UPS and potential therapeutics for this disease. HD model striatal
neurons with mutant huntingtin expression (105 CAG) showed
reduced proteasome activity and increased vulnerability to
proteasome inhibition, mitochondrial complex II inhibition, and
QA excitotoxicity compared to control striatal neurons expressing
wild type huntingtin (26 CAG). Specifically, PA28c enhanced
proteasome activities and improved cell survival after proteasome
inhibition (by MG132) and QA excitotoxicity, but not after
mitochondrial inhibition (by 3-NP).
In a related study, using a conditional transgenic mouse model
of HD, neuronal inclusions and HD-like symptoms were reversed
when mutant huntingtin protein expression was blocked [20].
These data indicate that continuous expression of mutant
huntingtin is required for the expression of HD pathology [20].
Such clearance of mutant huntingtin in neuronal cultures in HD
mice depended on proteasome function given that the irreversible
proteasome inhibitor lactacystin prevented the resolution of the
protein aggregate [21]. Previous studies have also demonstrated
that UPS inhibition decreases cell viability [22], increase
polyglutamine aggregation in Spinocerebellar ataxia type 3/
Machado-Joseph disease (SCA3/MJD) in vitro, and alter cell
morphology [23]. Mutant huntingtin overexpressing neuroblasto-
ma cells with ubiquitin cotransfection showed increased protein
aggregates and apoptic cell death, suggesting ubiquitin involve-
ment in HD pathological cell death [6]. Overexpression of
ubiquitin E3-ligase (Siah1) increased the nuclear translocation of
mutant huntingtin and cytotoxicity, indicating that ubiquitin
ligation is also critical in HD pathology [24]. A shorter half-life of
huntingtin delayed aggregate formation, but increased cellular
toxicity [25]. Therefore it appears that cell toxicity in part is
caused by unprocessed mutant huntingtin protein with the
extended CAG repeats. These data imply that aggregate
formation itself may not be a direct cause for the cell death, but
a cellular defense mechanism. In our study, the mutant huntingtin
overexpressing HD model striatal neurons did not show protein
Figure 2. Lentiviral gene transfer of PA28c and S5a, in control and HD model striatal neurons. (A) Schematic experimental outline of gene transfer and
differentiation of striatal neurons followed by exposure to HD model experimental toxins. HD model striatal cells were gene engineered with PA28c,
S5a. After verification of expression for the transferred genes, cells were grown in medium containing 1mg/ml of doxycyclin for 48h before toxin
treatment. After 24 h incubation in the toxic environment, medium was collected for the MTS assay and cells were harvested for proteasome activity
determination. (B) Semiquantitative Western blot of the huntingtin showing a slight decrease of protein levels by lenti-viral transduction of PA28c
gene into HD model striatal cells. Results are shown as percentage of levels of lenti-GFP control group (* p,0.05).
doi:10.1371/journal.pone.0000238.g002
HD Cell Survival by PA28c
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aggregates even though they demonstrated UPS dysfunc-
tion, which is similar to HD patients in early disease stages (grade
0–1)[9]. These results indicate that the mutant huntingtin itself (in
the pre-aggregation stage) can produce significant proteasome
dysfunction in HD. Generally, cytosolic mutant proteins may be
toxic[26] to cells, and so they need to be processed by the UPS or
other pathways such as lysosomes and autophagy [27]. However,
when the absolute amount of cytosolic mutant protein reaches
a certain limit, protein aggregations occur and consequently form
nuclear inclusion bodies [5,28]. In this scenario, aggregates are not
harmful per se but just by-products in the cell. Consequently,
simple aggregation inhibition may not be a proper solution for
abnormal protein handling in neurodegenerative diseases
[9,29,30].
Previously, we found significant proteasome dysfunction in the
several brain regions and skin fibroblasts from HD patients [9].
However, there are likely multiple interferences by mutant
huntingtin that can precipitate HD pathology in vulnerable brain
regions [9]. Impaired metabolic mitochondrial complex II–III
(MC II–III) energy production is also involved in the vulnerability
of the neurons in caudate-putamen area of HD patients [9,31].
Ruan et al. also found that striatal cells from mutant huntingtin
knock-in mice are selectively vulnerable to MC II–III inhibition
[32]. BDNF levels are down regulated in several brain regions of
HD patients [9]. Finally, by excitotoxicity, the N-methyl-D-
aspartate (NMDA) receptor agonist quinolinic acid (QA) destroy
medium sized spiny neuron in very similar pattern to that seen in
human HD pathology [33–35].
PA28c overexpression in this study caused improved UPS
function as assessed by known proteolytic activities of the
proteasome in both HD fibroblasts and HD model striatal
neurons. Critically, such PA28c gene transduction reduced the
HD relevant toxicity produced by proteasome inhibitor (MG132),
and/or excessive glutamate receptor (QA) mediated activity.
However, no neuroprotection was observed after mitochondrial
complex inhibition (3-NP). One potential explanation for this
result is that PA28c is a non-ATP dependent regulator of the UPS
[36], and therefore less connected to alterations of mitochondrial
metabolism. Given that QA and NMDA induced cell death is
preceeded by large increases in misfolded and ubiquitinated
Figure 3. Proteasome activities following lentiviral gene transfer of PA28c and S5a, in control and HD model striatal neurons. (A–F) Chymotrypsin-like
(A, D), PGPH (B, E) and trypsin-like (C, F) activities were detected. Both wild type (CTRL, 26 CAG, control striatal neurons) and mutant huntingtin
overexpressing HD model striatal neurons (Htt, 105 CAG, HD model striatal neurons) [16] were transduced with PA28c or S5a. Basal proteasome
activities were decreased in HD model striatal neurons compared to control cells with normal range of CAG repeats. However, the overexpression of
PA28c increased proteasome activities in both control and HD model striatal neurons. The overexpression of S5a decreased chymotrypsin-like
activities in HD model striatal neurons and decreased PGPH activities in control striatal neurons. In contrast, total trypsin-like activities were slightly
increased in both control and HD model striatal neurons after the gene transfer of S5a (1, p,0.05 between control and HD striatal neurons. *, p,0.05
between the gene transferred groups of control protein GFP and PA28c or S5a). The experiments were repeated three times in triplicate.
doi:10.1371/journal.pone.0000238.g003
HD Cell Survival by PA28c
PLoS ONE | www.plosone.org 5 February 2007 | Issue 2 | e238
proteins [37,38], the observed neuroprotection against both
MG132 and QA is understandable. Whereas mitocondrial toxicity
decreases the threshold for NMDA mediated toxicity to increase
calcium influx to the cells [39–41], there is no evidence that
NMDA receptor impairs mitochondrial function. The conse-
quence of such analysis is that PA28c could contribute to
reductions in both excitotoxicity and protein toxicity whereas
protection against the mitochondrial dysfunction would require an
additional type of intervention. Proteasome activators of the UPS
modulate different proteolytic enzyme activities by several
mechanisms. This is due to the different alterations of protein
structure by which the PA28 and PA700 regulators bind to the
20S proteasome core to help peptide substrates reach the catalytic
core beta subunits. For example, PA28g and S5a are participating
in two different major protein degradation pathways in the UPS:
PA28g is involved in non-ubiquitinated protein degradation, while
S5a is associated with ubiquitinated protein degradation [42].
PA28g is predominantly located in the nucleus, while S5a exists in
the cytosol [42,43]. Curiously, in our experiment, S5a over-
expression decreased cell survival in the response to MG132 and
QA in HD model striatal neurons. Perhaps the overexpression of
S5a (one out of nine subunits complex of PA700) is not sufficient to
accomplish functional effects. Alternatively, it could be a stoichio-
metric problem, in which there is unbalanced competition to form
the 26S proteasome complex [7]. Yet another problem with excess
amounts of free S5a may be the inhibition of proteasome
degradation by sequestering polyubiqutinated substrates from
reaching the proteasome [17,44].
It was recently reported that genetic reduction of PA28c (also
denoted REGc) did not alter the pathological phenotype or
inclusion body formation in the striatum of R6/2 HD mice [45].
We think this absence of neuroprotection by PA28c compared to
our positive findings can be explained by differences of
experimental approaches and HD models used. For example,
R6/2 mice always show increased proteasome activities in the
striatum [46], which therefore does not model the UPS
dysfunction seen in HD patients’ brains and HD fibroblasts [9].
However, HD transgenic mice with full-size mutant huntingtin
expression (YAC72 transgenic mice) do show UPS inhibition
resembling that seen in HD patients [46]. This at least indicates
that R6/2 transgenic mice do not model mature HD pathology
due to abnormal protein processing in the UPS. Moreover, the
HD R6/2 transgenic mice also completely lack QA-induced
striatal excitotoxicity in modeling HD pathology [47]. Conse-
quently, the lack of additional HD pathology by knock out of
PA28c function during development of R6/2 mice [45] may not
represent a challenge to our findings of neuroprotective effects by
PA28c enhanced UPS function.
In summary, these results demonstrate a role of mutant
huntingtin in protein toxicity and specifically provide therapeutic
targets and candidates for gene transfer to enhance proteasome
function. Although proteasome dysfunction is probably only one of
multiple factors involved in the dynamic and progressive disease
process of HD [9], our data at least demonstrate that proteasome
activators are relevant candidates for future comprehensive and
effective treatment approaches to HD.
Figure 4. Experimental exposure of PA28c (A–D) or S5a (E–G) overexpressing control and HD model striatal neurons to toxin modeling
pathophysiological processes observed in HD. (A) MG132 treated control (CTRL, 26 CAG) and HD model striatal neurons (Htt, 105 CAG) transduced
with PA28c. Shown are cell viabilities after 24 hours of exposure to MG132. (B–G) The reversible proteasome inhibitor, MG132 (B, E); the
mitochondrial inhibitor, 3-NP (C, F); and the excitotoxin, QA (D, G) were used at various concentrations to treat control and HD model striatal neurons.
HD model striatal neurons showed significantly decreased the resistance to those neuropathological toxins compared to control striatal neurons.
PA28c significantly improved cell survival, and S5a significantly decreased cell survival after exposure to MG132 and QA, but not 3-NP, respectively (1,
p,0.05 between wild-type and mutant huntingtin overexpressing striatal neurons. *, p,0.05 between the gene transferred groups of control protein
GFP and PA28c or S5a). The experiments were repeated three times in triplicate.
doi:10.1371/journal.pone.0000238.g004
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MATERIALS AND METHODS
Experimental Design
In the experiments, we performed gene transfer of several
proteasome activator subunits including PA28a, b and c, for the
20S proteasome, and S5a and p58 subunits of the PA700 for the
26S proteasome into normal and HD patient’s skin fibroblasts,
and control and HD model striatal cells. After determination of
the expression of the transduced genes using RT-PCR and
Western blot (Figure 1A), cells were differentiated as previously
described [16] (Figure 2). Cell cultured medium was collected for
MTS cytotoxicity test and cells were harvested for proteasome
activity determination. In addition, we administered HD relevant
toxins at various concentrations for 24 hours for cytotoxicity study.
Construction of Lentiviral Vectors and Lentiviral
Transduction of proteasome activators, PA28c and
S5a
The lentivirus vector system used in our studies was kindly
provided by Drs R. Zufferey and D. Trono, University of Geneva,
Switzerland [48]. The PA28a, b, c p58 and S5a cDNAs were
kindly provided by Dr. Rechsteiner (University of Utah [14,43])
and Dr. Tanaka [42], and cloned into pRRL.cPPT.PGK.
GFP.W.Sin-18 (Lenti-eGFP) replacing the eGFP with the PA28c
or S5a genes. Fibroblasts and striatal cells were transduced with
Lenti-eGFP as a transduction control, PA28c or S5a at a multi-
plicity of infection (MOI) of 5 to 20 as previously described [9].
Cell Culture
Normal and HD human fibroblasts used in this study were
obtained from the Coriell Cell Repository ([9] GM08399,
GM04689, GM04732). Fibroblasts were cultured in minimum
essential medium (MEM; Gibco, Carlsbad, CA) supplemented
with 15% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-
glutamine (Gibco), 0.1 mM nonessential amino acids (Gibco),
penicillin and streptomycin. Huntingtin inducible striatal cells
were cultured at 37uC and 33uC in DMEM, supplemented as
described previously [16,49]. The expression levels of huntingtin
protein were determined after administration of doxycycline
(1 mg/ml) for 24 hours using Western blot analysis (Figure 2B).
MG132 (Calbiochem), 3-NP (Sigma), QA (Sigma) were used at
the indicated concentrations in the cell cultures. After 24 hours of
treatment, medium was collected to determine cell viability by
a quantitative colorimetric assay, the modified MTS assay
(Promega). Harvested cells were lysed in 50 mM Tris pH8.0,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10 mg/mL
aprotinin, 25 mg/mL Leupeptin, 10 mg/mL Pepstatin, 1 mM
PMSF; all protease inhibitors purchased from Sigma). Homo-
genates were centrifuged at 14,0006 g for 30 min at 4uC. The
protein levels were determined using the Bio-Rad Protein Assay
(BIO-RAD, Hercules, CA). Samples containing equal amounts of
total protein were used for the determination of proteasome
activities and Western blots.
Reverse-transcriptase (RT) PCR for transfered gene
validation
RNA samples were extracted from harvested cells using Tri
Reagent (Sigma, St. Louis) and were reverse transcribed into
cDNA using the SuperscriptTM reverse transcriptase kit (Invitro-
gen, Carlsbad, CA) and oligo(dT)20 as primers. Reverse transcrip-
tase reaction were carried out at 50uC, for 50 min. Synthesized
cDNA template were amplified with forward primers for S5a (59-
ATCTATGGAAGAGCAGCGG-39) and PA28 c (59-GGGTA-
CAGCTCCTGATTCC-39) and the virus backbone reverse
primer, WPRE (59-AGCAGCGTATCCACATAGC-39). Human
b-actin primers (forward: 59-GGCGGCAACACCATGTACCCT
-39; reverse: 59-AGGGGCCGGACTCGTCATACT-39) were
used to determine cellular RNA expression level. PCR was
performed with G-Taq DNA polymerase (Labopass, Seoul, Korea)
with a denaturing step for 2 min at 94uC, followed by 40 cycles of
1min at 94uC, 1 min at 58uC, and 2 min at 72uC, and terminated
by an elongation step at 72uC for 7 min. PCR products were
visualized in 1% agarose gel electrophoresis.
Determination of proteasomal function
Using synthetic peptides, three different proteolytic activities were
measured to detect proteasome activities: (1) chymotrypsin-like
(after hydrophobic residue), (2) trypsin-like (after basic residues), or
(3) PGPH (after basic residues) activities [13]. These different
catalytic activities are due to the function of different subunits of
the catalytic core. In this study, proteasome function was
determined by continuously measuring the fluorescence of 7-
amido-4-methylcoumarin (AMC) (excitation 380 nm, emission
460 nm) generated from peptide-AMC linked substrates [50].
Reactions were conducted in a final volume of 200 ml containing
50 mM Tris-HCl buffer (pH 7.5) and 1 mM EDTA. After adding
samples to the reaction mixtures, reactions were initiated by the
following substrates: Suc-Leu-Leu-Val-Try-AMC (65 mM) for
chymotrypsin activity, Z-Leu-Leu-Glu-AMC (75 mM) for PGPH
activity and Boc-Leu-Arg-Arg-AMC (71 mM) for trypsin-like
activity. Reactions were followed for 240 min at 25uC and
enzymatic activities were expressed as fluorescence units (FU)/
min/mg protein.
Western blot
The protein expression levels were determined from the cell
extract using specific antibodies as previously described [9]: PA28c
(Calbiochem 1:2,500), S5a (Calbiochem, 1:1,000), huntingtin
(Chemicon, 1:5,000). Quantification of immunoreactive bands
was performed using densitometry. The results were confirmed by
duplicate measurements of the same samples.
Statistical analysis
All statistical analyses were carried out using JMP (version 3.1.6,
SAS Institute). Data were objectively compared between different
groups at different stages of disease using unpaired Student’s t test
and 2-way ANOVA followed by Turkey-Kramer posthoc analysis.
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